The Survival of Patients with Triple Negative Breast Cancer Undergoing Chemotherapy Along with Lifestyle Change Interventions

Background: The survival of patients with triple-negative breast cancer subtype undergoing chemotherapy along weight management, physical activity, and diet was examined. In addition, the relationship between Overall Survival (OS) expression P53 Ki 67 investigated. Methods: study conducted on 110 admitted to oncology clinics October 2009 July 2018. underwent five cycles, including Docetaxel, Epirubicin, Cyclophosphamide once every 21 days followed by two cycles Cyclophosphamide, 5-Fluorouracil. also received guidelines for exercise, diet, lifestyle change. Results: median mean follow-ups were 52.3 45.6 months respectively. Eight metastatic 103 under adjuvant therapy, 13 whom had relapses. relapse-free OS 44.4 49.2 P53-negative 64.2 months, eight relapsed in P53-positive group, group. more favorable negative group (P=0.021). DFS P53- 96.1% 76.3% suggesting a status Out patients, 20 died 90 are still alive. Conclusion: Combining change increases chance better response treatment reduction rate relapse during first three years. p53-negative patients.